肝癌组织及肝癌细胞株中TRAIL受体的检测

被引：1

作者：

肖明兵

黄介飞

倪润洲

朱净

张弘

魏群

江枫

鲍柏军

机构：

[1] 南通大学附属医院消化内科

来源：

南通大学学报(医学版) | 2006年 / 02期

关键词：

原发性肝细胞癌; 肿瘤坏死因子相关凋亡诱导配体; 受体; 逆转录聚合酶链反应;

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤];

学科分类号：

100214 ;

摘要：

目的:检测肿瘤坏死因子相关凋亡诱导配体(TNF related apoptosis inducing ligand,TRAIL)受体在原发性肝癌(PHC,简称肝癌)组织及肝癌细胞株HepG2及SMMC7721中的表达,以期选出与肝癌组织中TRAIL受体表达相近的细胞株。方法:收集原发性肝癌组织30例,以常规方法培养人肝癌细胞株HepG2及SMMC7721,以半定量RT-PCR法,对TRAIL受体的表达作半定量检测。结果:30例肝癌组织及HepG2细胞中均有TRAIL受体DR4(deathrecptor4)、DR5、DcR1(decoy receptor1)、DcR2的表达,而SMMC7721细胞中不表达DcR1;半定量结果显示肝癌组织及HepG2中DR4及DR5的表达量明显高于DcR1及DcR2;肝癌组织中4对受体间的表达量存在相关性,HepG2细胞中DR4的表达与DcR1及DcR2间存在相关性。结论:HepG2中TRAIL受体的表达类似于肝癌组织。

引用

页码：82 / 84+87 +87

页数：4

共 8 条

[1]

An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Pan G,Ni J,Wei YF,et al. Science . 1997

[2]

The receptor for the cytotoxic ligand TRAIL. Peter ME.Rorke K,Chinnaiyan AM,et al. Science . 1997

[3]

Antitumor effects of soluble TRAIL in human hepatocellular carcinoma. He SQ,Chen Y,Chen XP,et al. Chinese Journal of Oncology . 2003

[4]

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptor. Scheridan JP,Marster SA,Pitti PM,et al. Science . 1997

[5]

CCNU-de-pendent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is P53-independent but may in-volve enhanced cytochrome c release. Rohn TA,Wagenknecht B,Roth W,et al. Oncegene . 2001

[6]

Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cells. Herzer K,Ganten TM,Schulze-Bergkamen H,et al. Hepatology . 2005

[7]

Identification and characterization of newmember of the TNF family that induces apoptosis. Wiley SR,Schooley K,Smolak PJ,et al. Immunity . 1995

[8]

Trail:a molecule with multiple re-ceptor and control mechanisms. Griffith TS,Lynch DH. Current Opinion in Immunology . 1998

← 1 →